B2M and adenocarcinoma: To assess the impact of deleting either PTP1B or PTPN2 in NK cells on anti-tumor immunity we implanted B2m–/– MC38 adenocarcinoma cells lacking MHC-I [sensitive to NK cells but not T cells57] (Supplementary Fig. 11e, f) or a 70:30 mix of wild type MC38s (insensitive to NK cells) and B2m–/– MC38s (Fig. 6c, d) into the flanks of floxed control versus Ncr1-Cre;Ptpn1fl/fl or Ncr1-Cre;Ptpn2fl/fl male mice deficient for PTP1B or PTPN2 respectively in NK cells.